Gastrointestinal stromal tumours: Clinical overview, surgery and recent advances in imatinib mesylate therapy

Treatment of GISTs with imatinib has led to dramatic improvements in progression-free and overall survival, thereby rendering its use in the preoperative and postoperative treatment under intense investigation. New investigational agents are being developed and participation in promising clinical trials remains a standard of care.